Animal models of Alzheimer disease: historical pitfalls and a path forward

Cites (358)

Items 201–358 of 358

1. Levels of Soluble Apolipoprotein E/Amyloid-β (Aβ) Complex Are Reduced and Oligomeric Aβ Increased with APOE4 and Alzheimer Disease in a Transgenic Mouse Model and Human Samples*
   Tai, Leon M., Bilousova, Tina, Jungbauer, Lisa, Roeske, Stephen K., Youmans, Katherine L., Yu, Chunjiang, Poon, Wayne W., Cornwell, Lindsey B., Miller, Carol A., Vinters, Harry V. et al. · 2013 · Journal of Biological Chemistry
2. Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein γ-Secretase for the Treatment of Alzheimer's Disease
   R. Martone, Hua Zhou, K. Atchison, T. Comery, Jane Z. Xu, Xin-Yi Huang, Xioahai Gong, Mei Jin, A. Kreft, B. Harrison et al. · 2009 · Journal of Pharmacology and Experimental Therapeutics
3. Clinical aspects of inflammation in Alzheimer's disease
   Paul B. Rosenberg · 2005 · International Review of Psychiatry
4. Spatial learning and memory as a function of age in the dog.
   Elizabeth Head, R. Mehta, J. Hartley, M. Kameka, Brian J Cummings, Carl W. Cotman, William W. Ruehl, Norton William Milgram · 1995 · Behavioral Neuroscience
5. Vascular and parenchymal Aβ deposition in the aging dog: correlation with behavior
   Marie-Anne Colle · 2000 · Neurobiology of Aging
6. Tauopathy with paired helical filaments in an aged chimpanzee
   Rosen, Rebecca F., Farberg, Aaron S., Gearing, Marla, Dooyema, Jeromy, M. Long, Patrick, Anderson, Daniel C., Davis‐Turak, Jeremy, Coppola, Giovanni, Geschwind, Daniel H., Paré, Jean‐Francois et al. · 2008 · Journal of Comparative Neurology
7. BACE1 (β-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes
   Harrison, Steve M, Harper, Alex J, Hawkins, Julie, Duddy, Graham, Grau, Evelyn, Pugh, Pippa L, Winter, Panida H, Shilliam, Claire S, Hughes, Zoë A, Dawson, Lee A et al. · 2003 · Molecular and Cellular Neuroscience
8. Region-specific age at onset of β-amyloid in dogs☆
   Elizabeth Head, Richard McCleary, Fletcher F. Hahn, Norton William Milgram, Carl W. Cotman · 2000 · Neurobiology of Aging
9. M1 Muscarinic Agonists Can Modulate Some of the Hallmarks in Alzheimer's Disease: Implications in Future Therapy
   Abraham Fisher, Zipora Pittel, Rachel Haring, Nira Bar-Ner, Michal Kliger-Spatz, Niva Natan, Inbal Egozi, Hagar Sonego, Itzhak Marcovitch, Rachel Brandeis · 2003 · Journal of Molecular Neuroscience
10. Effects of the Uncompetitive NMDA Receptor Antagonist Memantine on Hippocampal Long‐term Potentiation, Short‐term Exploratory Modulation and Spatial Memory in Awake, Freely Moving Rats
    Carol Ann Barnes, Wojciech Danysz, Chris G. Parsons · 1996 · European Journal of Neuroscience
11. Relevance of Transgenic Mouse Models to Human Alzheimer Disease
    Debbi Ann Morrissette, Anna I. Parachikova, Kim N. Green, Frank M. LaFerla · 2008 · Journal of Biological Chemistry
12. Morphological and Biochemical Analyses of Amyloid Plaque Core Proteins Purified from Alzheimer Disease Brain Tissue
    Alex E. Roher, Kenneth C. Palmer, Edward C. Yurewicz, Melvyn J. Ball, Barry Greenberg · 1993 · Journal of Neurochemistry
13. The γ-Secretase Inhibitor N-[N-(3,5-Difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl Ester Reduces Aβ Levels in Vivo in Plasma and Cerebrospinal Fluid in Young (Plaque-Free) and Aged (Plaque-Bearing) Tg2576 Mice
    Thomas A. Lanz, Carol S. Himes, Giovanni Pallante, Lisa Adams, Shinji Yamazaki, Ben Amore, Kalpana Merchant · 2003 · Journal of Pharmacology and Experimental Therapeutics
14. APP Transgenic Mice Tg2576 Accumulate Aβ Peptides That Are Distinct from the Chemically Modified and Insoluble Peptides Deposited in Alzheimer's Disease Senile Plaques
    Walter M. Kalback, M. Desiree Watson, Tyler A. Kokjohn, Yu‐Min Kuo, Nicole Weiss, Dean C. Luehrs, John C. Lopez, Daniel C. Brune, Sangram S. Sisodia, Matthias Staufenbiel et al. · 2001 · Biochemistry
15. Hydroxyl Radicals, Iron, Oxidative Stress, and Neurodegenerationa
    John M.C. Gutteridge · 1994 · Annals of the New York Academy of Sciences
16. γ‐Secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila
    Craig A. Micchelli, William P. Esler, William Taylor Kimberly, Christine E. Jack, Oksana Berezovska, Anna Y. Kornilova, Bradley T. Hyman, Norbert Perrimon, Michael S. Wolfe · 2002 · The FASEB Journal
17. Microcebus murinus: a useful primate model for human cerebral aging and Alzheimer's disease?
    Nöelle Bons, François Rieger, Denis Prud’homme, Abraham Fisher, K.‐H. Krause · 2005 · Genes Brain & Behavior
18. The association between physical activity and dementia in an elderly population: the Rotterdam Study
    Renée F.A.G. de Bruijn, Elisabeth M. C. Schrijvers, Karen A. de Groot, Jacqueline C.M. Witteman, Albert Hofman D, Oscar H. Franco, Peter J. Koudstaal, M. Arfan Ikram · 2013 · European Journal of Epidemiology
19. Semantic Memory Functional MRI and Cognitive Function after Exercise Intervention in Mild Cognitive Impairment
    J. Carson Smith, Kristy A. Nielson, Piero Antuono, Jeri-Annette Lyons, Ryan J. Hanson, Alissa M. Butts, Nathan C. Hantke, Matthew Verber · 2013 · Journal of Alzheimer s Disease
20. Impairments in Fast Axonal Transport and Motor Neuron Deficits in Transgenic Mice Expressing Familial Alzheimer's Disease-Linked Mutant Presenilin 1
    Orly Lazarov, Gerardo A. Morfini, Gustavo F. Pigino, Archana Gadadhar, X. Chen, J. Robinson, H. Ho, Scott T. Brady, Sangram S. Sisodia · 2007 · Journal of Neuroscience
21. Early Amyloid Accumulation in the Hippocampus of SAMP8 Mice
    Jaume del Valle, Joaquim Duran‐Vilaregut, Gemma Manich, Gemma Casadesús, Mark A. Smith, Antoni Camins, Mercè Pallàs, Carme Pelegrı́, Jordi Vilaplana · 2010 · Journal of Alzheimer s Disease
22. Animal Models of Alzheimer's Disease: Therapeutic Implications
    Diana S. Woodruff‐Pak · 2008 · Journal of Alzheimer s Disease
23. Properties of scyllo–inositol as a therapeutic treatment of AD-like pathology
    Daniela Fenili, Mary Brown, Rebecca V. Rappaport, JoAnne McLaurin · 2007 · Journal of Molecular Medicine
24. EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study
    Vellas, B., Sol, O., J. Snyder, P., Ousset, P.-J., Haddad, R., Maurin, M., Lemarie, J.-C., Desire, L., P. Pando, M. · 2011 · Current Alzheimer Research
25. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation
    Irene Han-Juo Cheng, Jorge J. Palop, Luke Esposito, Nga Bien‐Ly, Fengrong Yan, Lennart Mucke · 2004 · Nature Medicine
26. Vitamin E for Alzheimer's disease and mild cognitive impairment
    Mokhtar Gad El Kareem Nasr Isaac, Rebecca Quinn, Naji Tabet · 2008 · Cochrane Database of Systematic Reviews
27. Development of AFFITOPE vaccines for Alzheimer's disease (AD) — From concept to clinical testing
    Achim Schneeberger, Markus Mandler, O. Otava, Wolfgang Zauner, Frank Mattner, Wolfgang Schmidt · 2009 · The journal of nutrition health & aging
28. Free radical damage, iron, and Alzheimer's disease
    Mark A. Smith, George L. Perry · 1995 · Journal of the Neurological Sciences
29. Neuroanatomical Abnormalities in Behaviorally Characterized APPV717F Transgenic Mice
    Jean‐Cosme Dodart, Chantal Mathis, Josep Saura, Kelly R. Bales, Steven M. Paul, Arielle Ungerer · 2000 · Neurobiology of Disease
30. β-Amyloid (Aβ) Deposition in the Brains of Aged Orangutans
    Gearing, M, Tigges, J, Mori, H, Mirra, S.S · 1997 · Neurobiology of Aging
31. Differentiation from human pluripotent stem cells of cortical neurons of the superficial layers amenable to psychiatric disease modeling and high-throughput drug screening
    Claire Boissart, Aurélie Poulet, Pauline Georges, Hélène Darville, E Julita, Richard Delorme, Thomas Bourgeron, Marc Peschanski, Alexandra Benchoua · 2013 · Translational Psychiatry
32. Metal protein attenuating compounds for the treatment of Alzheimer's dementia
    Elizabeth Lesley Sampson, Lydia Jenagaratnam, Rupert H. McShane · 2014 · Cochrane Database of Systematic Reviews
33. Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's Disease
    Benjamin W. Miller, Kristine C. Willett, Alicia R Desilets · 2011 · Annals of Pharmacotherapy
34. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice
    Thomas L. Kukar, Sonya Prescott, Jason L. Eriksen, Vallie M. Holloway, Michael Paul Murphy, Edward H. Koo, Todd Eliot Golde, Michelle M. Nicolle · 2007 · BMC Neuroscience
35. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older
    Eric Berg Larson, L. Wang, James D. Bowen, Wayne C. McCormick, Linda L Teri, Paul K. Crane, Walter A. Kukull · 2006 · Scandinavian Journal of Medicine and Science in Sports
36. Immunohistochemical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques
    Nikolaos G. Papaioannou, Peter C.J. Tooten, Anne Marie van Ederen, J. Böhl, Jaime Rofina, Thomas Tsangaris, Erik Gruys · 2001 · Amyloid
37. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease
    Claudia Schwab, Masato Hosokawa, Patrick L. McGeer · 2004 · Experimental Neurology
38. Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis’ still alive?
    Tayeb, Haythum O, Murray, Evan D, Price, Bruce H, Tarazi, Frank I · 2013 · Expert Opinion on Biological Therapy
39. Expression of human β‐secretase in the mouse brain increases the steady‐state level of β‐amyloid
    Ursula Bodendorf, Simone Danner, Frauke Fischer, Muriel Stefani, Christine Sturchler, Karl‐Heinz Wiederhold, Matthias Staufenbiel, Paolo Paganetti · 2002 · Journal of Neurochemistry
40. Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome
    Abdul Shukkur Ebrahim, Atsushi Shimohata, Takumi Akagi, Wenxin Yu, Mika Yamaguchi, Miyuki Murayama, Dehua Chui, Tamaki Takeuchi, Kenji Amano, Karthik Harve Subramhanya et al. · 2006 · Human Molecular Genetics
41. Neurofibrillary Pathology in Transgenic Mice Overexpressing V717F β-Amyloid Precursor Protein
    Eliezer Masliah, Abbyann Sisk, Margaret E. Mallory, Dora Games · 2001 · Journal of Neuropathology & Experimental Neurology
42. Changes in Cognition and Mortality in Relation to Exercise in Late Life: A Population Based Study
    Laura Elizabeth Middleton, Arnold Mitnitski, Nader Fallah, Susan Kirkland, Kenneth J. Rockwood · 2008 · PLoS ONE
43. Aβ40 is a major form of β-amyloid in nonhuman primates
    Marla Gearing, Johannes Tigges, Hiroshi Mori, Suzanne Samuels Mirra · 1996 · Neurobiology of Aging
44. Insights into Alzheimer disease pathogenesis from studies in transgenic animal models
    Schaeffer, Evelin L, Figueiró, Micheli, Gattaz, Wagner F · 2011 · Clinics
45. Lost in Transgenesis
    Jennifer Davis, Marjorie Maillet, Joseph M. Miano, Jeffery D. Molkentin · 2012 · Circulation Research
46. TC-1734: An orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects
    Gatto, Gregory J., Bohme, G Andrees, Caldwell, William S., Letchworth, Sharon R., Traina, Vincent M., Obinu, M. Carmen, Laville, Michel, Reibaud, Michel, Pradier, Laurent, Dunbar, Geoffrey et al. · 2004 · CNS Drug Reviews
47. Discovery of Begacestat, a Notch-1-Sparing γ-Secretase Inhibitor for the Treatment of Alzheimer’s Disease
    Scott C. Mayer, Anthony F. Kreft, Boyd L. Harrison, Magid A. Abou-Gharbia, Madelene M. Antane, Suzan Aschmies, Kevin P. Atchison, Michael A. Chlenov, Derek C. Cole, Thomas A. Comery et al. · 2008 · Journal of Medicinal Chemistry
48. Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42in patients with Alzheimer's disease
    Christoph Höck, Alessia S. Maddalena, Andreas Raschig, Franz Müller-Spahn, Gerhard Wilhelm Eschweiler, Klaus Huger, I Hewer, Harald Juergen Hampel, Thomas Müller-Thornsen, Wolfgang H. Oertel et al. · 2003 · Amyloid
49. Infusion of (+)-MK-801 and memantine — contrasting effects on radial maze learning in rats with entorhinal cortex lesion
    Wojciech Zajaczkowski, G. Quack, Wojciech Danysz · 1996 · European Journal of Pharmacology
50. Cognitive performance and biochemical markers in septum, hippocampus and striatum of rats after an i.c.v. injection of streptozotocin: a correlation analysis
    Jos Prickaerts, Thomas Fahrig, Arjan Blokland · 1999 · Behavioural Brain Research
51. Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats
    Philippe Chopin, Mike Briley · 1992 · Psychopharmacology
52. Natural Non-Trasgenic Animal Models for Research in Alzheimers Disease
    Manuel Sarasa, Pedro Pesini · 2009 · Current Alzheimer Research
53. Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimer’s disease. A meta-analysis
    Saeed Sadigh‐Eteghad, Mahnaz Talebi, Mehdi Farhoudi · 2012 · Neurosciences
54. Perturbed endoplasmic reticulum function, synaptic apoptosis and the pathogenesis of Alzheimer's disease
    Mark P. Mattson, Devin S. Gary, Sic L. Chan, Wenzhen Duan · 2001 · Biochemical Society Symposia
55. The Development of Anti-Amyloid Therapy for Alzheimer???s Disease
    Paul S. S. Aisen · 2005 · CNS Drugs
56. Behavioral and Psychological Symptoms of Dementia in developing countries
    Cleusa P. Ferri, David Ames · 2004 · International Psychogeriatrics
57. Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M1-preferring receptor agonists
    Julia N. Heinrich, John A. Butera, Tikva A. Carrick, Angela Kramer, Dianne M. Kowal, Tim Lock, Karen L. Marquis, Mark H. Pausch, Mike Popiolek, Shaiu-Ching Sun et al. · 2009 · European Journal of Pharmacology
58. Effects of Omega-3 Fatty Acids on Inflammatory Markers in Cerebrospinal Fluid and Plasma in Alzheimer’s Disease: The OmegAD Study
    Yvonne Freund‐Levi, Erik Hjorth, Catharina Lindberg, Tommy Cederholm, Gerd Faxén Irving, Inger Vedin, Jan E.W. Palmblad, Lars‐Olof Wahlund, Marianne Schultzberg, Hans Basun et al. · 2009 · Dementia and Geriatric Cognitive Disorders
59. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward
    Francesco Panza, Vincenzo Solfrizzi, Bruno Pietro Imbimbo, Rosanna Tortelli, Andrea Santamato, Giancarlo Logroscino · 2014 · Expert Review of Clinical Immunology
60. Structural Basis of C-terminal β-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer's Disease
    Sherry L. LaPorte, Sangeetha Subbarao Bollini, Thomas A. Lanz, Yasmina Noubia Abdiche, Alexander S. Rusnak, Wei-Hsien Ho, Dione T. Kobayashi, Ons Harrabi, Danielle C. Pappas, Erene W. Mina et al. · 2011 · Journal of Molecular Biology
61. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study
    Piotr Lewczuk, Johannes Kornhuber, Hugo Vanderstichele, Eugeen Vanmechelen, Hermann Esselmann, Mirko Bibl, Stefanie Wolf, Markus Otto, Udo Reulbach, Heike Kölsch et al. · 2007 · Neurobiology of Aging
62. The effects of a psychomotor activation programme for use in groups of cognitively impaired people in homes for the elderly
    Boey · 1999 · Pure Amsterdam UMC
63. Bis(7)‐tacrine attenuates β amyloid‐induced neuronal apoptosis by regulating L‐type calcium channels
    Hongjun Fu, Wenming Li, Yuanzhi Lao, Jialie Luo, Nelson T.K. Lee, Kelvin K.W. Kan, Hing Wai Tsang, Karl Wah Keung Tsim, Yuan‐Ping Pang, Zhi‐Wang Li et al. · 2006 · Journal of Neurochemistry
64. Latrepirdine (Dimebon®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model
    John Steele, Sam Gandy · 2013 · Autophagy
65. High β-Secretase Activity Elicits Neurodegeneration in Transgenic Mice Despite Reductions in Amyloid-β Levels
    Edward M. Rockenstein, Michael Mante, Michael F. Alford, Anthony Adame, Leslie A. Crews, Makoto Hashimoto, Luke Esposito, Lennart Mucke, Eliezer Masliah · 2005 · Journal of Biological Chemistry
66. Therapeutic agents for the treatment of cognitive dysfunction syndrome in senior dogs
    Gary M Landsberg · 2005 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
67. Mutant Presenilin 2 Transgenic Mouse: Effect on an Age‐Dependent Increase of Amyloid β‐Protein 42 in the Brain
    Fumitaka Oyama, Naoya Sawamura, Kimio Kobayashi, Maho Morishima‐Kawashima, Takashi Kuramochi, Mamoru Ito, Taisuke Tomita, Kei Maruyama, Takaomi C. Saido, Takeshi Iwatsubo et al. · 1998 · Journal of Neurochemistry
68. G enetically A ltered M ouse M odels: the G ood, the B ad, and the U gly
    Tamizchelvi Thyagarajan, Satish M. Totey, Mary Jo S. Danton, Ashok B. Kulkarni · 2003 · Critical Reviews in Oral Biology & Medicine
69. The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory
    Gerard R. Dawson, Susan D. Iversen · 1993 · Behavioural Brain Research
70. Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease
    Bruno Pietro Imbimbo, Simone Ottonello, Vincenza Frisardi, Vincenzo Solfrizzi, Antonio Greco, Davide Seripa, Alberto Pilotto, Francesco Panza · 2012 · Expert Review of Clinical Immunology
71. Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: Digital morphometric analyses
    Chi-Cheng Wu, Faisal Chawla, Dora Games, Russell E. Rydel, Stephen B. Freedman, Dale Schenk, Warren G. Young, John H. Morrison, Floyd E. Bloom · 2004 · Proceedings of the National Academy of Sciences
72. The progression of β-amyloid deposition in the frontal cortex of the aged canine
    Takao Satou, Brian J Cummings, Elizabeth Head, Kristy A. Nielson, Fletcher F. Hahn, Norton William Milgram, Peter Velázquez, David H. Cribbs, Andrea J. Tenner, Carl W. Cotman · 1997 · Brain Research
73. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys
    Decker, Michael W., Bannon, Anthony W., Curzon, Peter, Gunther, Karen L., Brioni, Jorge D., Holladay, Mark W., Lin, Nan-Horng, Li, Yihong, Daanen, Jerome F., Buccafusco, Jerry J. et al. · 1997 · The Journal of Pharmacology and Experimental Therapeutics
74. Mutant Presenilin 2 Transgenic Mice
    Naoya Sawamura, Maho Morishima‐Kawashima, Hatsue Waki, Kimio Kobayashi, Takashi Kuramochi, Matthew P. Frosch, Kai Ding, Mamoru Ito, Tae‐Wan Kim, Rudolph E. Tanzi et al. · 2000 · Journal of Biological Chemistry
75. Age-related progression of tau pathology in brains of baboons
    Christian Schultz · 2000 · Neurobiology of Aging
76. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy.
    Francine Gervais, Robert J. Chalifour, D. Garceau, X Kong, J Laurin, Richard William McLaughlin, Céline Morissette, Julie Paquette · 2001 · PubMed
77. A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice
    Joanne E. Sweeney, Christine F. Höhmann, Timothy H. Moran, JOSEPH T. COYLE · 1988 · Pharmacology Biochemistry and Behavior
78. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B
    Gary L. Wenk, Wojciech Zajaczkowski, Wojciech Danysz · 1997 · Behavioural Brain Research
79. AF150(S) and AF267B
    Abraham Fisher, Rachel Brandeis, Rachel Haring Nira Bar-Ner, Michal Kliger-Spatz, Niva Natan, Hagar Sonego, Itzhak Marcovitch, Zipora Pittel · 2002 · Journal of Molecular Neuroscience
80. Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
    Veerhuis, Robert · 2011 · Current Alzheimer Research
81. ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A Potent and Selective Cholinergic Channel Modulator with Neuroprotective Properties
    James Patrick Sullivan, Diana L. Donnelly‐Roberts, Clark A. Briggs, David J. Anderson, Murali Gopalakrishnan, Iris C. Xue, Marietta Piattoni-Kaplan, Eduardo J. Molinari, Jeffrey E. Campbell, David G. McKenna et al. · 1997 · Journal of Pharmacology and Experimental Therapeutics
82. Neurodegenerative mechanisms in alzheimer disease
    Bryce L. Sopher, Ken‐ichiro Fukuchi, Terrance J. Kavanagh, Clement E. Furlong, George M. Martin · 1996 · Molecular and Chemical Neuropathology
83. Pharmacological modulation of Alzheimer's β-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions
    Vahram H. Haroutunian, Nigel H. Greig, Xue‐Feng Pei, Tada Utsuki, R Gluck, Larisa D. Acevedo, Kenneth L. Davis, William Wallace · 1997 · Molecular Brain Research
84. Metrifonate for Alzheimer's disease
    Jess López-Arrieta, Lon S. S. Schneider · 2006 · Cochrane Database of Systematic Reviews
85. Effects of Age on Measures of Complex Working Memory Span in the Beagle Dog (Canis familiaris) Using Two Versions of a Spatial List Learning Paradigm
    P. Dwight Tapp, Christina T. Siwak, Jimena Estrada, D. Holowachuk, Norton William Milgram · 2003 · Learning & Memory
86. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders
    Rueter, Lynne E., Anderson, David J., Briggs, Clark A., Donnelly‐Roberts, Diana L., Gintant, Gary A., Gopalakrishnan, Murali, Lin, Nan‐Horng, Osinski, Mark A., Reinhart, Glenn A., Buckley, Michael J. et al. · 2004 · CNS Drug Reviews
87. Production of recombinant human type I procollagen homotrimer in the mammary gland of transgenic mice
    P. David Toman, Frank R. Pieper, Naomi Sakai et al. · 1999 · Transgenic Research
88. Dimebon improves learning in animals with experimental Alzheimer's disease
    N. N. Lermontova, Nikolay Lukoyanov, Tatiana P. Serkova · 2000 · Bulletin of Experimental Biology and Medicine
89. Bis（7）-tacrine attenuates beta amyloid-induced neuronal apoptosis by regulating L-type calcium channels
    Fu, Li, Lao et al. · 2006 · 中国生物学文摘
90. Cardiac Disease Associated With Increased Risk of Nonamnestic Cognitive Impairment
    Rosebud O. Roberts, Yonas E. Geda, David S. Knopman, Ruth H. Cha, V. Shane Pankratz, Bradley F. Boeve, Eric G. Tangalos, Robert J. Ivnik, Michelle M. Mielke, Ronald Carl Petersen · 2013 · JAMA Neurology
91. Intracranial Injection of Gammagard, a Human IVIg, Modulates the Inflammatory Response of the Brain and Lowers A in APP/PS1 Mice Along a Different Time Course than Anti-A Antibodies
    Tiffany L. Sudduth, Abigail Wolf Greenstein, Donna M. Wilcock · 2013 · Journal of Neuroscience
92. Galanthamine, an acetylcholinesterase inhibitor: A time course of the effects on performance and neurochemical parameters in mice
    Joanne E. Sweeney, Pamela S. Puttfarcken, Joseph T. Coyle · 1989 · Pharmacology Biochemistry and Behavior
93. The Relationship Between Physical Activity and Cognition in Older Latinos
    Jo Ellen Wilbur, David X. Márquez, Louis Fogg, R. S. Wilson, Beth A. Staffileno, Ruby L. Hoyem, M. C. Morris, Eduardo E. Bustamante, Alexis Manning · 2012 · The Journals of Gerontology Series B
94. A Rabbit Model of Alzheimer's Disease: Valid at Neuropathological, Cognitive, and Therapeutic Levels
    Diana S. Woodruff‐Pak, Alexis Agelan, Luis Del Valle · 2007 · Journal of Alzheimer s Disease
95. Gene expression profile in streptozotocin rat model for sporadic Alzheimer?s disease
    Edna Grünblatt, Siegfried Hoyer, Peter Franz Riederer · 2004 · Journal of Neural Transmission
96. Reduced corpus callosum, fornix and hippocampus in PDAPP transgenic mouse model of Alzheimer's disease
    Francisco Gonzalez-Lima, Jason D. Berndt, Jonathan E. Valla, Dora Games, Eric M. Reiman · 2001 · Neuroreport
97. Diffuse beta-amyloid plaques and hyperphosphorylated tau are unrelated processes in aged dogs with behavioral deficits
    Marco Pugliese, Joan Mascort, Nicole Mahy, Isidró Ferrer · 2006 · Acta Neuropathologica
98. Effects of AZD3480 on Cognition in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase IIb Dose-Finding Study
    Lutz Frölich, on behalf of the Sirocco Investigators, Tim J. Ashwood, Jonas Nilsson, Göran Eckerwall · 2011 · Journal of Alzheimer s Disease
99. Dietary polyphenol-derived protection against neurotoxic β-amyloid protein: from molecular to clinical
    Scott Darryl Smid, Jesper L.V. Mååg, Ian Musgrave · 2012 · Food & Function
100. Neurotrophic and Neuroprotective Actions of (−)- and (+)-Phenserine, Candidate Drugs for Alzheimer’s Disease
     Anna M. Lilja, Yu Luo, Qian‐sheng Yu, Jennie Röjdner, Yazhou Li, Ann M. Marini, Amelia Marutle, Agneta K. Nordberg, Nigel H. Greig · 2013 · PLoS ONE
101. The Effect of Aging on Pars Compacta of the Substantia Nigra in Rhesus Monkey
     Zaeem Azfer Siddiqi, Alan Peters · 1999 · Journal of Neuropathology & Experimental Neurology
102. Promising anti-Alzheimer’s dimer bis(7)-tacrine reduces β-amyloid generation by directly inhibiting BACE-1 activity
     Hongjun Fu, Wenming Li, Jialie Luo, Nelson T.K. Lee, Mingtao Li, Karl Wah Keung Tsim, Yuan‐Ping Pang, Moussa B. H. Youdim, Yifan Han · 2007 · Biochemical and Biophysical Research Communications
103. Cerebral Amyloid-Beta Protein Accumulation with Aging in Cotton-Top Tamarins: A Model of Early Alzheimer's Disease?
     Cynthia Ann Lemere, Jiwon Oh, Heather A. Stanish, Ying Peng, Imelda Pepivani, Anne M. Fagan, Haruyasu Yamaguchi, Susan V. Westmoreland, Keith G. Mansfield · 2008 · Rejuvenation Research
104. Phenserine
     Jochen Klein · 2007 · Expert Opinion on Investigational Drugs
105. Effects of anticholinesterase drugs tacrine and E2020, the 5-HT(3) antagonist ondansetron, and the H(3) antagonist thioperamide, in models of cognition and cholinergic function.
     D.L. Kirkby, D.N.C. Jones, Jen Barnes · 1996 · PubMed
106. Mesenchymal Stem Cells Facilitate Fracture Repair in an Alcohol-Induced Impaired Healing Model
     Thomas S. Obermeyer, David Yonick, Kristen L. Lauing, Stuart R. Stock, Rachel K. Nauer, Patrick K. Strotman, Ravi Shankar, Richard L. Gamelli, Michael D. Stover, John J. Callaci · 2012 · Journal of Orthopaedic Trauma
107. Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice
     Frédérique Bard, Michael Fox, Stuart W. Friedrich, Peter A. Seubert, Dale Schenk, Gene G. Kinney, Ted A. Yednock · 2012 · Experimental Neurology
108. Rescuing clinical trials in the United States and beyond: A call for action
     Zubin J. Eapen, John Paul Vavalle, Christopher Bull Granger, Robert A. Harrington, Eric David Peterson, Robert M. Califf · 2013 · American Heart Journal
109. Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer’s disease
     Debby Van Dam, Katrien Coen, Peter Paul De Deyn · 2007 · Psychopharmacology
110. Age-Dependent Neuroplasticity Mechanisms in Alzheimer Tg2576 Mice Following Modulation of Brain Amyloid-β Levels
     Anna M. Lilja, Jennie Röjdner, Tamanna Mustafiz, Carina M. Thomé, Elisa Storelli, Daniel Gonzalez, Christina Unger Lithner, Nigel H. Greig, Agneta K. Nordberg, Amelia Marutle · 2013 · PLoS ONE
111. Bis(7)-tacrine, a novel acetylcholinesterase inhibitor, reverses AF64A-induced deficits in navigational memory in rats
     Jing Liu, Wing Lok Ho, Nelson T.K. Lee, Paul R. Carlier, Yuan‐Ping Pang, Yifan Han · 2000 · Neuroscience Letters
112. Metrifonate effects on acetylcholine and biogenic amines in rat cortex
     Francesca Mori, Gabriel Ricardo Cuadra, Ezio Giacobini · 1995 · Neurochemical Research
113. Carboxyl end-specific monoclonal antibodies to amyloid β protein (Aβ) subtypes (Aβ40 and Aβ42(43)) differentiate Aβ in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys
     Shinichiro Nakamura, Akira Tamaoka, Naoya Sawamura, Shin’ichi Shoji, Hiroyuki Nakayama, Fumiko Ono, Ippei Sakakibara, Yasuhiro Yoshikawa, Hiroshi Mori, Naoaki GOTO et al. · 1995 · Neuroscience Letters
114. Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man
     M. Wienrich, Dieter H. Meier, Helmut A. Ensinger · 2001 · Life Sciences
115. The Genetics of Alzheimer’s Disease
     Chen K. Chai · 2007 · American Journal of Alzheimer s Disease & Other Dementias®
116. Nonhuman primates as models for aging and Alzheimer's disease.
     Mary Lou Voytko · 1998 · PubMed
117. Clinical Features of Sporadic and Familial Alzheimer's Disease
     Martin N. Rossor, Nick C. Fox, Peter A. Freeborough, Richard J. Harvey · 1996 · Neurodegeneration
118. Generation of transgenic monkeys with human inherited genetic disease
     Anthony W.S. Chan, Shang‐Hsun Yang · 2009 · Methods
119. Ultrastructural analyses of β-amyloid in the aged dog brain: Neuronal β-amyloid is localized to the plasma membrane
     Reidun Torp, Elizabeth Head, Carl W. Cotman · 2000 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
120. Physical Activity and Cognitive Trajectories in Cognitively Normal Adults
     Rachel Gabriella Pizzie, Halley Hindman, Catherine M. Roe, Denise M Head, Elizabeth Grant, John C. Morris, Jason J. Hassenstab · 2013 · Alzheimer Disease & Associated Disorders
121. Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimer's disease
     Saeed Sadigh‐Eteghad, Mahnaz Talebi, Mehdi Farhoudi · 2012
122. Region- and cell-type-specific pattern of tau phosphorylation in dog brain
     Jerzy Węgiel, Henryk M. Wı́sniewski, Zenon Sołtysiak · 1998 · Brain Research
123. Distribution of β-amyloid in the canine brain
     Y Hou, R. G. White, Marketta Bobik · 1997 · Neuroreport
124. Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data
     Camilla Niva, JOANNA R. PARKINSON, Fredrik Olsson, Erno van Schaick, Johan Lundkvist, Sandra A. G. Visser · 2013 · European Journal of Clinical Pharmacology
125. Quantitative evaluation of MRI and histological characteristics of the 5xFAD Alzheimer mouse brain
     Nicholas G. Spencer, Leslie Bridges, Kay Elderfield, K. Amir, Brian Austen, Franklyn A. Howe · 2013 · NeuroImage
126. Metal protein attenuating compounds for the treatment of Alzheimer's dementia
     Elizabeth Lesley Sampson, Lydia Jenagaratnam, Rupert H. McShane · 2012 · Cochrane Database of Systematic Reviews
127. Abnormal neuronal and glial argyrophilic fibrillary structures in the brain of an aged albino cynomolgus monkey ( Macaca fascicularis )
     Wijit Kiatipattanasakul, Hiroyuki Nakayama, Supattra Yongsiri, Somchai Chotiapisitkul, Shinichiro Nakamura, Hideaki Kojima, K. Doi · 2000 · Acta Neuropathologica
128. Effects of γ-Secretase Inhibition on the Amyloid β Isoform Pattern in a Mouse Model of Alzheimer’s Disease
     Erik Portelius, Bin Zhang, Mikael K. Gustavsson, Gunnar Brinkmalm, Ann Brinkmalm, Henrik Zetterberg, Virginia M.‐Y. Lee, John Q. Trojanowski, Kaj Blennow · 2009 · Neurodegenerative Diseases
129. Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden
     Rachel A. Yotter, Jimit J. Doshi, Vanessa Clark, Jitka Sojkova, Yun Zhou, Dean Foster Wong, Luigi Ferrucci, Susan M. Resnick, Christos A. Davatzikos · 2013 · Neurobiology of Aging
130. Immunohistochemical analysis of presenilin 2 expression in the mouse brain: distribution pattern and co-localization with presenilin 1 protein
     Véronique Blanchard, Christian Czech, Bruno Bonici, Nicole Clavel, Micheline Gohin, Karine Dalet, Frédéric Revah, Laurent Pradier, Assunta Impérato, Saliha M. Moussaoui · 1997 · Brain Research
131. Ispronicline: A Novel α4β2 Nicotinic Acetylcholine Receptor-Selective Agonist With Cognition-Enhancing and Neuroprotective Properties
     Patrick M. Lippiello, Sharon R. Letchworth, Gregory J. Gatto, Vincent M. Traina, Merouane Bencherif · 2006 · Journal of Molecular Neuroscience
132. Baxter International Inc.
     2019 · Corporate Philanthropy Report
133. Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor
     Namisha Patel, Edward L. Spangler, Nigel H. Greig, Qian‐sheng Yu, Donald K. Ingram, Robert C. Meyer · 1998 · Neuroreport
134. Comparable amyloid β-protein (Aβ) 42(43) and Aβ40 deposition in the aged monkey brain
     Kazutomi Kanemaru, Takeshi Iwatsubo, Yasuo Ihara · 1996 · Neuroscience Letters
135. Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice.
     Sylvia E. Perez, Muhammad Nadeem, Katherine R. Sadleir, Joanna Matras, Christy M. Kelley, Scott Counts, Robert J. Vassar, Elliott Jay Mufson · 2012 · Europe PMC (PubMed Central)
136. Long-term Effects of Galantamine on Cognitive Function in Alzheimer's Disease: A Large-Scale International Retrospective Study
     Shane Kavanagh, Bart van Baelen, Barbara Schäuble · 2011 · Journal of Alzheimer s Disease
137. International Participation in Cardiovascular Randomized Controlled Trials Sponsored by the National Heart, Lung, and Blood Institute
     Esther Kim, Thomas Carrigan, Venu Menon · 2011 · Journal of the American College of Cardiology
138. Pharmacokinetics of the M1-agonist talsaclidine in mouse, rat, rabbit and monkey, and extrapolation to man
     Andreas Leusch, Wolfgang Tröger, Andreas Greischel · 2000 · Xenobiotica
139. NerveCenter: Phase III Alzheimer trial halted: Search for therapeutic biomarkers continues
     Kurt Samson · 2010 · Annals of Neurology
140. Transgenic Nonhuman Primate Models for Human Diseases: Approaches and Contributing Factors
     Yongchang Chen, Yuyu Niu, Weizhi Ji · 2012 · Journal of genetics and genomics/Journal of Genetics and Genomics
141. Was Phenserine a Failure or Were Investigators Mislead by Methods?
     Robert E. Becker, Nigel H. Greig · 2012 · Current Alzheimer Research
142. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
     2000 · Neurology
143. Nonprogressive transgene-related callosal and hippocampal changes in PDAPP mice
     Jon Valla, Lonnie E. Schneider, Francisco Gonzalez-Lima, Eric M. Reiman · 2006 · Neuroreport
144. Direct Reprogramming into Desired Cell Types by Defined Factors
     Masaki Ieda · 2013 · The Keio Journal of Medicine
145. Impact of muscarinic agonists for successful therapy of Alzheimer’s disease
     Abraham Fisher, Rachel Brandeis, Rachel Haring, Nira Bar-Ner, Michal Kliger-Spatz, Niva Natan, Hagar Sonego, Itzhak Marcovitch, Zipora Pittel · 2002 · Journal of neural transmission. Supplementum
146. A mutation in Alzheimerʼs disease destroying a splice acceptor site in the presenilin-1 gene
     Jordi Pérez‐Tur, Susanne Froelich, Guy Prihar et al. · 1995 · Neuroreport
147. Memantine approved to treat moderate to severe Alzheimer’s disease
     Karen S. Marder · 2004 · Current Neurology and Neuroscience Reports
148. Amyloid-β immunotherapy CAD106 passes first safety test in patients with Alzheimer disease
     Katie Kingwell · 2012 · Nature Reviews Neurology
149. New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease
     Christiane Rose, Katell Peoc’h, Stéphanie Chasseigneaux, Claire Paquet, Julien Dumurgier, Fanchon Bourasset, Frédéric Calon, Jean Laplanche, Jacques Hugon, Bernadette Allinquant · 2012 · BMC Neuroscience
150. The Role of Complement and Activated Microglia in the Pathogenesis of Alzheimer's Disease
     Piet Eikelenboom · 1996 · Neurobiology of Aging
151. Use of statins
     Lawrence E. Ramsay, E. J Wallis, I. U. Haq · 1998 · BMJ
152. O1‐06‐03: Preclinical characterization of LY2886721: A BACE1 inhibitor in clinical development for early Alzheimer's disease
     Patrick C. May, Leonard N. Boggs, Richard A. Brier, David O. Calligaro, Martin Citron, Theresa A. Day, Suizhen Lin, Terry D. Lindstrom, Dustin J. Mergott, Scott A. Monk et al. · 2012 · Alzheimer s & Dementia
153. O4‐12‐04: EVP‐6124, a selective alpha‐7 partial agonist, has positive effects on cognition and clinical function in mild‐to‐moderate Alzheimer's disease patients: Results of a six‐month, double‐blind, placebo controlled, dose ranging study
     Dana C. Hilt, Maria S. Gawryl, Gerhard Koenig · 2012 · Alzheimer s & Dementia
154. Practical Considerations of Genetic Rodent Models for Neurodegenerative Diseases
     Kindiya D. Geghman, Chenjian Li · 2011 · Methods in molecular biology
155. The Genetics of Alzheimer’s Disease
     Lars Bertram · 2007 · Springer eBooks
156. EHT0202 in Alzheimer's Disease: a 3-Month, Randomized, Placebo- Controlled, Double-Blind Study
     Bruno J. Vellas, Olivier Sol, P.- J. Snyder · 2011 · Current Alzheimer Research
157. Drugs and Therapies
     2009
158. Enocuraging news in Alzheimer's prevention and treatment. Research continues to underscore the value of cardiovascular health in relation to brain function.
     2013 · PubMed